Using a patient-derived fibroblast ciliation assay to perform high throughput drug screen and candidate therapeutic compound validation for Bardet-Biedl syndrome (BBS)
Using a patient-derived fibroblast ciliation assay to perform high throughput drug screen and candidate therapeutic compound validation for Bardet-Biedl syndrome (BBS)
使用患者来源的成纤维细胞纤毛检测对 Bardet-Biedl 综合征 (BBS) 进行高通量药物筛选和候选治疗化合物验证
批准号：
449358
负责人：
Pearson Alexander L
金额：
$1.27万
依托单位：
依托单位国家：
加拿大
项目类别：
Studentship Programs
财政年份：
2020
资助国家：
加拿大
项目状态：
已结题
起止时间：
2020-12-01 至 2021-12-01
中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Bardet-Biedl syndrome (BBS) is a rare autosomal recessive genetic disorder caused by defective structure and/or function of the primary cilia. BBS is characterized by developmental anomalies, obesity, and a progressive retinal degeneration. Most BBS patie
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金
